There has been great progress in genomic knowledge, technical innovation and affordable computing power since the sequencing of the human genome in 2003 but one essential part of the puzzle has been missing. Massive amounts of data are not very valuable until you can integrate it all for a picture of the whole. 

Your genomic sequence is a great start but only offers a snapshot of what you brought to the table at conception or acquired during your lifetime. What is necessary is a panoramic view if you want clinically useful information. The Bio-Windows™ AI System and the 3-Risk™ analysis tool provides that view.

EVERY DISEASE IS UNIQUE

All complex diseases are the result of gene-environment interactions over time. What you eat, drink and breathe, your lifestyle and where you live and even how you think and feel impact how your genes do their jobs. By altering our gene and protein expression patterns, environmental factors along with our genetic variability create the individual differences we see in disease susceptibility and prescription drug sensitivity.

The Bio-Windows™ AI System is a very sophisticated artificial intelligence program that analyzes and stores the genomic, clinical and personal information from a growing number of patients that use the technology.  Comparing your information with a central repository of genomic profiles, patient analysis survey profiles and reference data provides a more precise disease diagnosis, prognosis and the risk of recurrence.

PATTERN RECOGNITION

When you classify 1000 patients diagnosed with the same disease, breast cancer for example, using the BioWindows™ system, a pattern begins to emerge grouping patients into subsets. The disease stops being generic and becomes more specific. The more patients that are diagnosed using the system the more finely tuned it becomes. Within the subsets you will uncover the most successful therapy with the least side effects – personalized precision medicine.

Imagine how precise the subsets become when you have a database comprised of 100,000 or 1,000,000 patients. What is even more exciting than a more precise therapy is that the increasing numbers may start to uncover specific actionable conditions that are interfering with the proper functioning of the genome – personalized prevention!

Written by: Bill Schaser, Director of Education